#Biofire diagnostics trial#
#Biofire diagnostics plus#

Zheng X., Polanco W., Carter D., Shulman S. Rapid Identification of Pathogens from Pediatric Blood Cultures by Use of the FilmArray ® Blood Culture Identification Panel.

#Biofire diagnostics trial#

Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testingīanerjee R., Teng C.B., Cuningham S.A., Ihde S.M., Steckelberg J.M., Moriarty J.P., Shah N.D., Mandrekar J.N., Patel R.ĬLINICAL INFECTIOUS DISEASES 2015 61(7):1071-1080 Antimicrobial Resistance Management Solutions page.Performance data for the detection of antimicrobial resistance genes can be found in the BioFire Blood Culture Identification 2 Panel Instructions for Use. Specificity / Negative Percent Agreement (NPA)Īcinetobacter calcoaceticus-baumannii cp. Sensitivity / Positive Percent Agreement (PPA) Sample Type: positive Blood Culture mediaĬlinical sensitivity and specificity of the BIOFIRE ® Blood Culture Identification 2 Panel Pathogen Clinical Infectious Diseases 2015 61:1071-80ħRay et al. The potential benefits of fast and comprehensive testing of bloodstream infections may include guided appropriate antibiotic therapy, decreased hospital length of stay 7, reduced hospital costs and reduced patient morbidities and mortality.ġ The stated performance is the aggregate of the prospective data from the clinical study.Ģ The stated performance is the aggregate of the prospective data from the clinical study.ģSepsis Alliance: Sepsis Fact Sheet 2018.ĤRhodes et al., Intensive Care Med. The BIOFIRE ® BCID2 Panel can provide the essential combination of speed, accuracy and comprehensiveness to enable a rapid, definitive identification of a pathogen directly from positive blood cultures. Obtaining rapid blood culture organism identification, combined with the local antibiogram, allows for the timely adjustment of a broad-spectrum empiric antimicrobial therapy to a narrow, targeted patient treatment 6. Moreover, it is best practice according to the Guidelines 3 to narrow down antimicrobial therapy as soon as pathogens are identified, in order to reduce the occurrence of antimicrobial resistances. However, it is estimated that early empiric antibiotic therapy is inappropriate in about 30% of patients 5. The International Guidelines for the Management of Sepsis and Septic Shock recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens within 1 hour of recognition of the disease 4. 43 targets at onceīIOFIRE ® BCID2 Panel targets: Gram+ Bacteriaįighting sepsis: a top healthcare challenge todayĮarly identification and treatment of sepsis is essential to combat one of the leading causes of hospital patient deaths 3.

#Biofire diagnostics plus#

BIOFIRE ® FILMARRAY ® Pneumonia plus PanelĢThe stated performance is the aggregate of the prospective data from the clinical study.BIOFIRE ® FILMARRAY ® Gastrointestinal Panel.BIOFIRE ® FILMARRAY ® Respiratory Panels.BIOFIRE ® FILMARRAY ® Meningitis/Encephalitis Panel.Taken together, the BIOFIRE ® FILMARRAY ® panels comprise the largest infectious disease pathogen menu commercially available. Accurate: The average positive agreement rate (or sensitivity) across all pathogens on the BCID2 panel is 99%, and the negative agreement rate (or specificity) is 99.8% 2.īIOFIRE ® BCID2 is one of five FDA-cleared and CE-marked panels for use on the BIOFIRE ® systems.BCID2 detects 10 antimicrobial resistance genes and emerging pathogens like C.auris and S.maltophilia Comprehensive: Simultaneously tests forĤ3 targets and identifies pathogens in more thanĩ out of 10 positive blood cultures.The BIOFIRE ® BCID2 Panel is designed for the BIOFIRE ® systems, an FDA, CE-IVD, and TGA certified multiplex PCR system that integrates sample preparation, amplification, detection and analysis.

With just one test you can identify pathogens more than 9 out of 10 positive blood cultures in about 1 hour with only 2 minutes of hands-on time. The BIOFIRE ® Blood Culture Identification 2 (BCID2) Panel tests for a comprehensive list of 33 pathogens and 10 antibiotic resistance genes associated with bloodstream infections. Simple, comprehensive pathogen ID from blood cultures